Investigational drug · Phase 2
AskBio009
Also called: BAX 335
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hemophilia B.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AskBio009"
First trial start
2013
Feb 11, 2013
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AskBio009", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hemophilia B
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AskBio009" as an intervention, largest first.
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia BActive, not recruiting
Baxalta now part of ShireTakeda (TAK)
NCT01687608 · 30 participants · Start Feb 11, 2013 · Primary completion Jan 17, 2030
Drug: AskBio009 · For: Hemophilia B
Sites: Los Angeles, California; Sacramento, California; San Diego, California · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
Konkle BA, Walsh CE, Escobar MA, et al. · Blood 2021
- Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release.
Lengler J, Coulibaly S, Gruber B, et al. · Mol Ther Methods Clin Dev 2020
- Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.
Weber A, Engelmaier A, Voelkel D, et al. · Mol Ther Methods Clin Dev 2018
Also in development for Hemophilia B
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.